# OnCo record braf-v600e-colorectal (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/braf-v600e-colorectal/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "braf-v600e-colorectal" ;
  schema:name "BRAF V600E-mutant colorectal cancer"@en ;
  schema:alternateName "BRAF-mutant colorectal cancer"@en, "BRAF V600E metastatic colorectal cancer"@en, "BRAF-mutated bowel cancer"@en ;
  schema:description "BRAF V600E bowel cancer carries the same mutation as many melanomas, but BRAF drugs alone did nothing here because the tumour re-routes its growth signal through EGFR. Blocking both with encorafenib and cetuximab, now given with chemotherapy from the start, has doubled survival in a subtype that used to be the worst."@en ;
  schema:url <https://onco.cc/cancers/braf-v600e-colorectal/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/BRAF_(gene)> ;
  schema:citation <https://en.wikipedia.org/wiki/BRAF_(gene)>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1428> ;
  onco:tag "subtype-page" ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:targets <https://onco.cc/targets/braf/>, <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/mek/>, <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/encorafenib/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/binimetinib/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/colorectal-cancer-signalling/> ;
  onco:terms <https://onco.cc/terms/msi/>, <https://onco.cc/terms/sidedness/>, <https://onco.cc/terms/cms-subtypes/>, <https://onco.cc/terms/ctdna/> ;
  onco:trials <https://onco.cc/trials/beacon-crc/>, <https://onco.cc/trials/breakwater/>, <https://onco.cc/trials/nct05217446/>, <https://onco.cc/trials/nct06008119/> ;
  onco:people <https://onco.cc/people/scott-kopetz/>, <https://onco.cc/people/josep-tabernero/>, <https://onco.cc/people/elena-elez/> ;
  onco:pipeline <https://onco.cc/trials/nct05217446/>, <https://onco.cc/trials/nct06008119/>, <https://onco.cc/trials/breakwater/>, <https://onco.cc/drugs/encorafenib/> ;
  onco:standardOfCare <https://onco.cc/trials/breakwater/>, <https://onco.cc/drugs/encorafenib/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/trials/beacon-crc/>, <https://onco.cc/drugs/encorafenib/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/trifluridine-tipiracil/>, <https://onco.cc/drugs/fruquintinib/>, <https://onco.cc/drugs/regorafenib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/trials/keynote-177/>, <https://onco.cc/trials/checkmate-8hw/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/capox/>, <https://onco.cc/drugs/oxaliplatin/> .